secwatch.observer — SEC 8-K summary
======================================

Issuer:     TherapeuticsMD, Inc. (TXMD)
CIK:        0000025743
Form:       8-K
Filed at:   2023-05-15T23:59:59+00:00
Accession:  0001193125-23-145019
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TherapeuticsMD Q1 net loss narrows to $2.3M from $17.9M; continuing ops loss $0.24/share
--------------------------------------------------------------------------------

- Net loss from continuing operations $2.3M ($0.24/share) vs $17.9M ($2.08) in Q1 2022.
- License and service revenues $0.4M, down from $0.7M due to transition to royalty-based business.
- Total operating expenses fell 82.8% to $3.1M, reflecting business transformation and reduced infrastructure.
- Net loss from discontinued ops $1.3M ($0.13/share) vs $31.1M ($3.62), as wind-down continues.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/25743/000119312523145019/0001193125-23-145019-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/25743/000119312523145019/d481253d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-145019

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer